Fibrogen announces clinical trial supply agreement with regeneron pharmaceuticals to evaluate fibrogen's immuno-oncology assets, fg-3165 (anti-galectin 9) and fg-3175 (anti-ccr8), in combination with libtayo® in upcoming clinical trials

San francisco, june 03, 2024 (globe newswire) -- fibrogen, inc. (nasdaq: fgen) today announced a clinical trial supply agreement with regeneron pharmaceuticals to evaluate fibrogen's immuno-oncology assets, fg-3165 and fg-3175, in combination with regeneron's anti-pd-1 therapy, libtayo® (cemiplimab), in patients with solid tumors.
FGEN Ratings Summary
FGEN Quant Ranking